Health Policy Life Science Medicare Pharmaceuticals 
Health Populi
OCTOBER 8, 2019
More savings would accrue through the quicker adoption of value-based payment models, the authors assert, where clinicians take on financial risk for managing population health. Pricing failure, the second big waste factor, is predominantly challenged by pharmaceutical/prescription drug pricing based on this research. patients).
Health Populi
MARCH 11, 2021
[Note: I may be biased as a University of Michigan graduate of both the School of Public Health and Rackham School of Graduate Studies in Economics]. health care, patient assistance programs, Medicare Advantage plans, and the bundling of proven high-value preventive services into the Affordable Care Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
JUNE 24, 2021
The economic and healthcare system impacts of this were explored in the Post-Covid Healthcare Landscape , delivered by Fitch Solutions’ Jamie Davies and Beau Noafshar, leaders in the Pharmaceuticals, Healthcare, and Medical Devices groups. spends on NASA.
Health Populi
OCTOBER 28, 2019
patients’ negative views of the pharmaceutical industry in this study was the opioid epidemic. Over one-half of Americans blame pharmaceutical companies as most responsible for the opioid crisis, followed by physicians, whom 39% of health consumers blame, and patients, whom 38% of people blame. Exacerbating U.S.
Health Populi
FEBRUARY 4, 2020
voters in 2020 quite like supporting Medicare’s ability to negotiate drug prices with pharmaceutical companies, shown by the October 2019 Kaiser Family Foundation Health Tracking Poll. This morning we don’t have a transcript of the speech ahead of the event, but one topic remains high on U.S. Few issues unite U.S.
Health Populi
JUNE 3, 2021
adults note that expanding Medicare to including hearing aids, dental and vision coverage would be their top or an important priority, shown in the second line in the bar chart on public priorities. States to negotiate with drug companies to get lower prices on Rx meds in their state, and. On the cost-front, 90% of U.S.
Health Populi
MARCH 6, 2019
is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. That would be profits made by pharmaceutical companies, cited by 80% of respondents. consumers were asked.
Expert insights. Personalized for you.
260 
Let's personalize your content